Boule Diagnostics publishes Q3 2026 earnings presentation
Bitget2026/10/28 16:08- Boule Diagnostics’ third-quarter 2026 sales fell 24.4% to SEK 96.2 million; organic sales declined 19.4%.
- Adjusted operating loss reached SEK 4.5 million versus a SEK 12 million profit; gross margin held at 41.1% versus 41.2%.
- Diagnostics sales dropped 30%, primarily reflecting supply-chain disruptions to 3-part instrument deliveries; demand for 5-part human and veterinary instruments was weak.
- OEM sales declined 6% to SEK 31.5 million; adjusted operating margin improved to 24.6% from 19.3%.
- Operating cash flow rose to SEK 6.9 million from SEK 1 million; available liquidity totaled SEK 21.6 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
